4. 原発性側索硬化症 ［臨床試験数：6，薬物数：12（DrugBank：7），標的遺伝子数：17，標的パスウェイ数：29］
Searched query = "Primary lateral sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/20/2019, 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03929068 | May 13, 2019 | 15 July 2019 | Sinemet for Spasticity and Function in Amyotrophic Lateral Sclerosis and Primary Lateral Sclerosis | Sinemet in ALS and PLS | Amyotrophic Lateral Sclerosis;Motor Neuron Disease | Drug: carbidopa-levodopa;Drug: Placebo Oral Tablet | Washington University School of Medicine | Recruiting | 18 Years | N/A | All | 15 | Phase 1 | United States | |
| 2 | EUCTR2018-000142-18-FI | 09/05/2018 | 21 May 2018 | Feasibility and effects of subcutaneously given combination of dexmedetomidine and ketamine in ALS patients receiving palliative care | Feasibility and pharmacodynamics of subcutaneously given combination of dexmedetomidine and ketamine infusion in ALS patients receiving palliative care | Amyotrophic lateral sclerosis (ALS) MedDRA version: 20.1 Level: LLT Classification code 10036704 Term: Primary lateral sclerosis System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Dexdor Pharmaceutical Form: Concentrate for concentrate for solution for infusion INN or Proposed INN: DEXMEDETOMIDINE CAS Number: 113775-47-6 Trade Name: Ketanest-S Pharmaceutical Form: Infusion INN or Proposed INN: ESKETAMINE CAS Number: 33643-46-8 | Turku University Hospital | Authorised | Female: yes Male: yes | 20 | Phase 4 | Finland | |||
| 3 | NCT03067857 | September 2016 | 18 June 2018 | Autologous Bone Marrow-Derived Stem Cell Therapy for Motor Neuron Disease | Autologous Purified Bone-Marrow-Derived Stem Cell Therapy for Motor Neuron Disease | Motor Neuron Disease;Amyotrophic Lateral Sclerosis;Primary Lateral Sclerosis;Progressive Muscular Atrophy;Progressive Bulbar Palsies | Biological: Stem Cells | Stem Cells Arabia | Not recruiting | 24 Years | 70 Years | All | 40 | Phase 1/Phase 2 | ||
| 4 | NCT02868567 | March 2016 | 9 September 2019 | Use of Dalfampridin in Primary Lateral Sclerosis | A Multicenter, 18-week Open Label Safety and Efficacy Trial of Dalfampridine in Primary Lateral Sclerosis | Motor Neuron Disease, Upper | Drug: dalfampridine | Weill Medical College of Cornell University | Hospital for Special Surgery, New York | Recruiting | 18 Years | 99 Years | All | 35 | Phase 1 | United States |
| 5 | EUCTR2011-004798-99-DE | 27/02/2013 | 27 October 2014 | Safety and Efficacy of SOD1 Inhibition By Pyrimethamine in Familial (ALS) | Safety and Efficacy of SOD1 Inhibition By Pyrimethamine in Familial (ALS) - Pyrimethamine In Familial ALS | Familial amyotrophic lateral sclerosis (FALS) MedDRA version: 14.1 Level: LLT Classification code 10036704 Term: Primary lateral sclerosis System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Daraprim Pharmaceutical Form: Tablet INN or Proposed INN: PYRIMETHAMINE CAS Number: 58-14-0 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- | Weill Medical College of Cornell University | Not Recruiting | Female: yes Male: yes | 40 | United States;Germany;Italy | ||||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | NCT00324454 | May 2006 | 19 February 2015 | Levetiracetam for Cramps, Spasticity and Neuroprotection in Motor Neuron Disease | A Pilot Trial of Levetiracetam for Cramps, Spasticity and Neuroprotection in Motor Neuron Disease | Motor Neuron Disease;Amyotrophic Lateral Sclerosis;Primary Lateral Sclerosis;Progressive Muscular Atrophy | Biological: Levetiracetam | Duke University | UCB Pharma | Not recruiting | 18 Years | N/A | Both | 20 | Phase 2 | United States |